Sten K Johnson Foundation award “Development of a predictive and stratifying biomarker panel in pancreatic cancer tissue”

Development of a predictive and layered biomarker panel in pancreatic cancer tissue

Pancreatic cancer is one of the deadliest of cancers with an average survival rate of 6-8 months and 5-year survival of max 5-6%. The goal now is to define a diagnostic / predictive and stratifying tissue marker panel in pancreatic cancer. This in order to improve and design a more tailor-made treatment and define subgroups that better respond to different types of therapy.

Reccan Diagnostics AB


Previous
Previous

Reccan Diagnostics successfully raises SEK 15M in a new share issue

Next
Next

Winner of the Lund University and Sparbanken Skåne award for future innovation